<SEC-DOCUMENT>0001746473-21-000005.txt : 20210510
<SEC-HEADER>0001746473-21-000005.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510164925
ACCESSION NUMBER:		0001746473-21-000005
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLIANT THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001746473
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474272481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39303
		FILM NUMBER:		21908013

	BUSINESS ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-481-6770

	MAIL ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plrx-20210510.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d,d:5282b1c531c64e06a16228ff3107eca0--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>plrx-20210510</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF84OS9mcmFnOmE1NTQxYmFkOTUyYzRlYjlhMTk1ZDJiZjc4ZmY2NGUyL3RhYmxlOjdiMzY0ZTJjNGQ0MzRhZjVhZmUzNTlkYzVlMmNjYjg0L3RhYmxlcmFuZ2U6N2IzNjRlMmM0ZDQzNGFmNWFmZTM1OWRjNWUyY2NiODRfMC0xLTEtMS0xNzM_424735ed-3240-4de7-9193-4c4c8870da23">0001746473</ix:nonNumeric><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF84OS9mcmFnOmE1NTQxYmFkOTUyYzRlYjlhMTk1ZDJiZjc4ZmY2NGUyL3RhYmxlOjdiMzY0ZTJjNGQ0MzRhZjVhZmUzNTlkYzVlMmNjYjg0L3RhYmxlcmFuZ2U6N2IzNjRlMmM0ZDQzNGFmNWFmZTM1OWRjNWUyY2NiODRfMS0xLTEtMS0xODA_7bd15869-ce02-468d-9e9a-d0759f4e04fd">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="plrx-20210510.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5282b1c531c64e06a16228ff3107eca0_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDA3_ad22ad4a-b061-4b3e-b96c-a9611c2e2cb6">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18xMDk5NTExNjI5MjI5_54a9e36d-a7ba-43d9-b3b5-a91099a2f630">May&#160;10, 2021</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDA5_8fa51eb2-98f2-416c-bed0-fde9eac6e0c1">PLIANT THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;padding-left:269.85pt;padding-right:269.85pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTAtMS0xLTQy_ed3a7428-957e-41e6-9d07-9ec21a40af94">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTEtMS0xLTQ0_06d60eed-031f-46a4-803d-6a8f22a2ea77">001-39303</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTItMS0xLTQ2_fbb55439-e469-4e09-bcb8-64b5ab06a4ce">47-4272481</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTc1NA_96455e93-3363-4b1f-b259-ffb50ab1cd84">260 Littlefield Avenue,</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTg0NA_53924cbe-f453-4699-bf56-27004d4707dd">South San Francisco,</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTg1Mw_9ad3cae7-359a-4239-956d-6a64cdfde958">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTItMS0xLTQ4_c6195df0-2527-4be4-aa5a-28a931a25044">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDEx_128faadc-71dc-4798-a58e-398e9e069556">650</ix:nonNumeric>) <ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDIw_909cc578-d280-46a9-85d8-82f0ce7bdbe2">481-6770</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF8wLTAtMS0xLTEzOQ_0555803d-4ddc-421d-b465-e0964e134d9a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF8yLTAtMS0xLTEzOQ_dffcf2ba-a908-48eb-b7f4-f6a1cb7e118e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF80LTAtMS0xLTEzOQ_6bbb8740-dc3e-47cc-b3ec-add4c504780e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF82LTAtMS0xLTEzOQ_7a9360ca-ae9b-45c7-bb5d-22585d4d68df">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTAtMS0xLTE0MQ_43c6640c-3fab-4ee7-8df4-7567b2243ffd">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTItMS0xLTE0Mw_0d246cb2-283f-49e0-a470-e692c76dc724">PLRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTQtMS0xLTE0NQ_ab4484e2-96d2-473e-9f38-0c696b7905ae">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;<ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDIz_8dcd9de6-a6ce-46bf-948a-19ae5b4cc555">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<ix:nonNumeric contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDI2_5c64f026-5f91-4e6b-a800-941efd0d1336">&#9744;</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5282b1c531c64e06a16228ff3107eca0_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;10, 2021, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company&#8217;s financial results for the first quarter ended March&#160;31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</span></div><div id="i5282b1c531c64e06a16228ff3107eca0_7"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.&#160;</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="plrx-8kxexhibit991.htm">Press Release issued by the Company dated M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="plrx-8kxexhibit991.htm">ay 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="plrx-8kxexhibit991.htm">, 2021.</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5282b1c531c64e06a16228ff3107eca0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLIANT THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;10, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Keith Cummings</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Cummings, M.D., MBA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plrx-8kxexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib118c3d3157c4d1b8df19e1409168544_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><img alt="image_01.jpg" src="image_01.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pliant Therapeutics Provides Corporate Update and <br>Reports First Quarter 2021 Financial Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021<br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- PLN-74809 Phase 2a 12-week trials in IPF and PSC Currently on Track to Complete Enrollment </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">by the End of 2021 and First Half of 2022, Respectively</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> - May 10, 2021 - </font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc.&#160;(Nasdaq&#58; PLRX) (&#8220;the Company&#8221;), a clinical stage biotechnology company focused on discover</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ing and&#160;developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported first quarter 2021 financial results.</font></div><div><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;During the first quarter, we continued the strong momentum of advancing our broad and novel clinical and development-stage portfolio,&#8221; said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. &#8220;With this progress and a financial runway taking us into 2023, we are well positioned to advance toward our objective of bringing potentially transformative treatments to patients in need.&#8221;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter and Recent Highlights</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">PLN-74809 Phase 2a positron emission tomography (PET) imaging trial preliminary data expected in the first half 2021. </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This open-label, dose ranging trial is evaluating target receptor occupancy levels of PLN-74809 in the lungs of IPF patients across multiple single-dose cohorts utilizing a PET tracer of the integrin &#945;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#946;</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">6</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The goal of the trial is to confirm the ability of PLN-74809, a dual selective inhibitor of &#945;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#946;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">6</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;&#945;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#946;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to penetrate highly fibrotic areas of the lung where </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#945;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#946;</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">6</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expression is highest and bind to its target receptor.  Additionally, the trial will establish a pharmacokinetic&#47; pharmacodynamic (PK&#47;PD) relationship between PLN-74809 plasma exposure and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#945;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#946;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">6</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> receptor occupancy, allowing us to build a PK&#47;PD model that will inform dose selection in later stage trials.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">PLN-74809 Phase 2a INTEGRIS trial in idiopathic pulmonary fibrosis (IPF) continued to build momentum, currently on track to complete enrollment by the end of 2021.  </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary endpoints of this 12-week randomized, dose-ranging, double-blind, placebo-controlled trial are the evaluation of PLN-74809&#8217;s safety, tolerability, and pharmacokinetics in IPF patients. The Company will also evaluate exploratory efficacy endpoints including Quantitative Lung Fibrosis, or QLF, imaging as well as pulmonary function tests.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">PLN-74809 Phase 2a INTEGRIS trial in primary sclerosing cholangitis (PSC) continued to advance, currently on track to complete enrollment in the first half 2022.  </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary endpoints of this 12-week randomized, dose-ranging, double-blind, placebo-controlled trial are the evaluation of PLN-74809&#8217;s safety, tolerability, and pharmacokinetics in PSC patients. The Company will also evaluate exploratory efficacy endpoints including fibrosis biomarkers such as Pro-C3 and ELF, changes in ALP, and liver imaging.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:14.15pt">Successful completion of PLN-1474 Phase 1 trial and t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">ransfer of </font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">PLN-1474 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">to Novartis</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">. </font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Phase 1 trial of PLN-1474 was a safety, tolerability, and pharmacokinetics dose-escalating first-in-human trial that enrolled 84 healthy volunteers. PLN-1474 was rapidly absorbed and well tolerated with no dose-or treatment-limiting toxicities or severe&#47; serious adverse events observed. In preclinical studies, PLN-1474 was observed to </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">selectively block the &#945;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:1.55pt;vertical-align:baseline">v</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#946;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:1.55pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">integrin-mediated activation of TGF-&#946;, reducing liver fibrosis in animal models. Following the successful completion of this study, PLN-1474 has been transferred to Novartis.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OVID-19 Preparedness</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company continues to develop and maintain policies and procedures to enable us to operate safely and productively during the COVID-19 pandemic. The Company has experienced delays in clinical trial operations which have impacted and may further impact the expected timing of data readouts. The Company continues to work closely with clinical sites to continue site initiation and operation activities in compliance with study protocols while observing government and institutional guidelines.  </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2021 Financial Results</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.53pt">Research and development expenses were&#160;$18.5 million, as compared to&#160;$13.9 million&#160;for the prior-year quarter. The increase was due primarily to employee related expenses and higher costs related to the advancement of several programs and ongoing Phase 1&#47;2 clinical trials.</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.53pt">General and administrative expenses were&#160;$6.6 million, as compared to&#160;$4.0 million&#160;for the prior-year quarter. The increase was due to higher personnel-related and professional services expenses.</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.53pt">Net loss of&#160;$22.9 million&#160;as compared to a net income of&#160;$11.0 million&#160;for the prior-year quarter due to a decrease in related party revenue driven by the achievement of a first-patient-first-dose milestone in the first quarter of 2020 for the PLN-1474 Phase 1 trial.</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.53pt">As of&#160;March&#160;31, 2021, the Company had cash, cash equivalents and short-term investments of $264.1 million. The Company believes it has sufficient funds to meet its operating and capital requirements into 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About&#160;Pliant Therapeutics, Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of &#945;v&#223;6 and &#945;v&#223;1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF, PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of &#945;v&#223;1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#143fdc;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.pliantrx.com</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;and follow us on </font><font style="color:#143fdc;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Twitter</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#143fdc;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#143fdc;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Facebook</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and&#160;</font><font style="color:#143fdc;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">YouTube</font><font style="color:#000d1b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statements contained in this press release regarding matters that are not historical facts are &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;intend,&#34; and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding our product candidates, including their development and therapeutic potential, the advancement of our clinical and preclinical pipeline, including the timing, enrollment and results of our clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical trials, clinical supply and plans and our financial position and cash runway. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risk that we may not realize the intended benefits of our collaboration, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34; in our Annual Report on Form 10-K filed with the SEC on March 16, 2021, as updated by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which we are filing with the SEC today, each available on the SEC's website at www.sec.gov.  Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor and Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Christopher Keenan</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vice President, Investor Relations and Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;pliantrx.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="ib118c3d3157c4d1b8df19e1409168544_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:66.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Revenue &#8212; related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">28,938&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(18,527)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(13,919)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(6,566)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(4,011)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(25,093)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(17,930)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(Loss) income from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(22,919)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,008&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Interest and other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">63&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net (loss) income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(22,856)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,029&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Less&#58; Undistributed earnings to preferred stockholders</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,029)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss attributable to common stockholders</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(22,856)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss per share, attributable to common stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.64)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.64)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Shares used in computing net loss per share attributable to common stockholders&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">35,645,205&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,897,669&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">35,645,205&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,897,669&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Comprehensive income (loss)&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(22,856)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net unrealized gain (loss) on short-term investments</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total other comprehensive income </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">14&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">60&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Comprehensive income (loss)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(22,842)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,089&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="ib118c3d3157c4d1b8df19e1409168544_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31,<br>2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">December 31,<br>2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">50,819&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">50,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">213,281&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">226,012&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Tax credit receivable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">83&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">83&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,180&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,498&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">270,537&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">290,754&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,266&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other non-current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">275,254&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">295,526&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Accounts payable</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,886&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,023&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Accrued liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">7,364&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9,576&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">10,250&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,599&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other long-term liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">866&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,085&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">12,465&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Common stock</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">404,868&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">400,918&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Accumulated deficit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(140,684)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(117,828)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(18)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(32)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">264,169&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">283,061&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">275,254&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">295,526&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>plrx-20210510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plrx="http://www.pliantrx.com/20210510" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pliantrx.com/20210510">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20210510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20210510_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20210510_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20210510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pliantrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>plrx-20210510_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20210510.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>plrx-20210510_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20210510.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended" id="i76e805f825424d6a821581b637404e00_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plrx-20210510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_8bc778ac-19cf-4d7d-8d04-8aaec5a5f47f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7baf0275-fa2c-46e1-b542-7eda7140b24f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dfebfd2b-1b3e-4cf7-a947-0bb626eb3687_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_05053e38-1601-48a2-9f5c-854fe1db49e3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_236151ca-ff8b-4cf6-a26b-f3c22ea695be_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bf969767-3d15-4174-af81-a3cf94428f3e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a60fc6fc-6d4e-4501-b2d1-ee0992ecccfb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_786e8875-4ea2-49be-9166-2b2d9900e743_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2ed62a97-e05a-40d5-bed0-e8451870259e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1324608b-fc8f-4970-8ef1-bb58323169c1_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0ec8998e-ce90-4c75-a417-57c1309e7d98_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_adc7e616-ed9e-4b08-883d-9268529e104f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_75fc8001-dea0-41e2-bf24-b5d81528efca_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8527941b-7686-4ac0-bca3-a7268c38507f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_e8bcfc55-b94c-4d0e-a549-ae2447b992a7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_55ce9a76-15bb-4447-acdf-bb8cfdfa8407_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1bcc7596-7d3e-4675-9105-e0d5c73d585b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_49bb95b9-16e2-4672-9145-62120266e82f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7375083c-ccc5-40ee-9c86-d79321e1620d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6cd4a684-27b5-4084-af80-fb7b9211dedb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_78f0bf3c-e28b-431a-a585-346ef69e0568_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_45ca9755-12c2-45f7-988b-4f549d8ac953_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_e251f649-9e31-48fe-ae95-eb55810781d0_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plrx-20210510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6c91e95f-45f3-4aa2-959f-75cfb0d3f44b,g:dfcdae0f-0467-4987-b587-ccdc8142ef1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20210510.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fbe39012-34f9-452c-a7ab-ca5bfd2277a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_DocumentType_fbe39012-34f9-452c-a7ab-ca5bfd2277a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_da4c1eb5-6672-40d1-978c-a6c5354d70d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_DocumentPeriodEndDate_da4c1eb5-6672-40d1-978c-a6c5354d70d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c8993fff-cfbf-4e4b-82ef-c8c25f106d61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityRegistrantName_c8993fff-cfbf-4e4b-82ef-c8c25f106d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c773e428-a031-4629-98c4-1270c8272a43" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c773e428-a031-4629-98c4-1270c8272a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8d81eb56-e86b-4819-a50b-18f046227a6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityFileNumber_8d81eb56-e86b-4819-a50b-18f046227a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9695bbe8-f55d-4499-9ce2-4d81bb5ea4a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityTaxIdentificationNumber_9695bbe8-f55d-4499-9ce2-4d81bb5ea4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba1ff2e8-6e03-459f-8765-1583fbe43d55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityAddressAddressLine1_ba1ff2e8-6e03-459f-8765-1583fbe43d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_35992645-8ed2-4d59-b4e8-5aeef8770622" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityAddressCityOrTown_35992645-8ed2-4d59-b4e8-5aeef8770622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e48268d3-be99-4923-88e3-e5e3f4ca15ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityAddressStateOrProvince_e48268d3-be99-4923-88e3-e5e3f4ca15ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fbcb930e-16d7-492d-8b56-1e8015662e37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityAddressPostalZipCode_fbcb930e-16d7-492d-8b56-1e8015662e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7e4e26b8-27cf-4867-914b-7ec628066621" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_CityAreaCode_7e4e26b8-27cf-4867-914b-7ec628066621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a64d0159-059f-4645-830e-fe966c85a4ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_LocalPhoneNumber_a64d0159-059f-4645-830e-fe966c85a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d9da7f0d-2776-4743-83f8-1a483a0cf1a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_WrittenCommunications_d9da7f0d-2776-4743-83f8-1a483a0cf1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b77400c2-5875-461b-ab73-e220766b0a2b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_SolicitingMaterial_b77400c2-5875-461b-ab73-e220766b0a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0453c564-3d77-4114-9cd6-b5398930c12b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_PreCommencementTenderOffer_0453c564-3d77-4114-9cd6-b5398930c12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a59bc958-f257-482b-a03b-34d134abf1ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a59bc958-f257-482b-a03b-34d134abf1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c248ea68-9634-41b0-8aec-dae9fcb273e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_Security12bTitle_c248ea68-9634-41b0-8aec-dae9fcb273e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b11ad5d4-6964-4d22-89f7-10b037446b3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_TradingSymbol_b11ad5d4-6964-4d22-89f7-10b037446b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_18d0373d-9cba-428b-a1c5-f4b47721760d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_SecurityExchangeName_18d0373d-9cba-428b-a1c5-f4b47721760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_13784d20-e2ed-4cf5-979d-c2011900f482" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityEmergingGrowthCompany_13784d20-e2ed-4cf5-979d-c2011900f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_4447bb41-25d0-427c-97f5-08b4277f4592" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityExTransitionPeriod_4447bb41-25d0-427c-97f5-08b4277f4592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7522c4ea-fd75-4e36-b126-2067adba9e50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_EntityCentralIndexKey_7522c4ea-fd75-4e36-b126-2067adba9e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f50731ff-440e-4dff-b81d-e855d6d73a6b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47931c93-b930-4f19-b55d-2c03da8ff091" xlink:to="loc_dei_AmendmentFlag_f50731ff-440e-4dff-b81d-e855d6d73a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: C0# 2(  A$! Q$!_\0
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MS&'@E213W1@:)TY0^) FF2T445 PHHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=YKD<,8W6&DCRE/]^0<AO?@TIR44V_Z_K;[RX>]9+^OZW^XZ7PGHB:)HT<9
M,TI,LK=]S<D?F:W:**\B<G.3D^IZ,8J*L@HHHJ2@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *IZG>?8K&24<R8Q&O\ >;L*N5SFH7(N;V20_-;V?5?[TG48]:UI
M0YI&5:IR1\S+^RC:ME(Q)8_:+PMU ;E5_.FE7N09USY]\=D(_BBB/!/YBK'D
M&11;2$EIB9KECP40\J*,M,K7" A[G]U:C',<9ZG'UKNO_7]?U9'FV3_K^O\
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M 'O-%%>=?%WQ7K'A/1K&XT>(O)-,R28[ +F@#T6BOEK_ (7/XW_YXO\ D?\
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M^F_WU_G7G_[.?_(P7W_7 _S% 'TC1110 5'/,EO \TAPB#)-25P_Q9UL:+X
MU$K)LFN(S'$PZAJ /G&0W'CGXI\@%GN0"",Y1&_PJQ\3-'/@[XA/+8CR@S>?
M%Z+S70_ #1?[1\6W&K2?-]E4@Y[E@:Z7]HK1 UG8ZPB$N'\IB!T&": /8?#&
MIIJ_ARQO(V#!HE!(]0!FM>O(O@!KBWWA!],+9>S;N?[Q)KUV@ I#T-+2'H:
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M_P!=X_Z5])7?ANV\5?#F#3+A1F2U 1R/NGU%?-OQ%_Y*K<_]=X_Z5]7^&_\
MD6]/_P"N"T ?+'@S7+_X:>/S:W<;I"TOE2QD\8)P&_ <U]:VMS%>6L=Q X>*
M1=RL.XKQ'X\^!C<6B>)+"$F6(A9U0<MGO^ %6_@3XZ&IZ:WA^]E/VFV7,18]
M5Z "@#T+X@_\B3J7_7%OY&OG;X%?\CY']!7T3\0?^1)U+_KBW\C7SM\"O^1\
MC^@H ^L**** "O/_ (S?\DVU/_KG_45Z!7G_ ,9O^2;:G_US_J* /(OV>?\
MD<9O^N+_ ,A7T[7S%^SS_P CC-_UQ?\ D*^G: "BBB@ HHHH **** "BBB@
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M?^S5]?ZK9G4-+N+53@RH5!KQKPQ\$+W0_$UOJDEZK+')O*@CUSZ4 >XT444
M%%%% !1110!\3^)G6/X@W3L<*MZ23Z#?7U+9_$CPI'9PH=6CR% /!KS37?@)
MJ&JZW=WR7RA9I6< L.,DGTK/_P"&=]4_Z"*_]]#_  H ]B_X65X3_P"@M'^1
MH_X65X3_ .@M'^1KQW_AG?5/^@BO_?8_PH_X9WU3_H(K_P!]C_"@#WC1?$ND
M^(/,_LR[6X\O[^WM6M7FWPM^'%SX#?4'N;GSC=!0 #G&,UZ30!Y=\>/^2?3?
M[Z_SKS_]G/\ Y&"^_P"N!_F*]D^(GA.7QCX9DTR"41NS @D^AKFOAC\,+OP-
MJ=Q=7%RLJRQ[  10!ZE114-VLSVDJV[!92OR$]C0!\D?%K6F\1?$&=(7W1(5
MBC'HW0_K7T)X.\/7>G_#&UT^RF2UOY;8?O73(5_4BO,K7X":RWB1;^\O(?)^
MT^>VU\D_-NQTKZ$C18HU1%"JHP .U 'DNH7?Q7\/W";!9ZM9J"7,4 0C\S65
M_P +YNM,G\C5_#ETC*<,P8 #]*]QZUF:KX=TC6X&@U+3X;F-A@JXZ_E0!YE<
M_&KPGKFBW5I=EK<S0LH#_-@D$#M7@7AK58?#WC:ROXIBUO;W ;<.-RU[YXC^
M &A:BQFTN:2Q<#B*-1M/YUQ+?L[ZZ'.R\MRH/&7_ /K4 ?2-I.+FS@G4Y$D:
MN/Q&:E/0UD>%]/O=+\/6ME?R+)<1+M9E.1CM6QVH ^//B+_R56Y_Z[Q_TKZO
M\-_\BWI__7!:\D\3_!6_USQA-K,=XBQO(KA2PSQ^%>R:7:-8:5;6C'+11A"?
M7% %ND(R"#T-+10!\M_&_P #G0M<_M>SAQ9W1R^T<(W3]:I_ K_D?(_H*^EO
M%7ART\4Z!<:9=H&5QE"?X6'0UYO\/_@_>>#_ !(-1EO!)&N, $9- 'L5%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@".""*VA6*&-4C48"J,"H8=/MH+J6YCC EE.7;UJU10!5ET^VGOH+R2,&>
M$1MZ9ZU6U/0-.U9U>Z@!D48$B\-CTSUQ6G10!1TW1['28V2S@6/=]YL?,WU/
M>JE]X6TF_N6N);?;(W+&,[=Q]3CK6S10!!9V5O86RV]K"D42]%10!4]%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>plrx-20210510_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plrx-20210510.xsd" xlink:type="simple"/>
    <context id="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF84OS9mcmFnOmE1NTQxYmFkOTUyYzRlYjlhMTk1ZDJiZjc4ZmY2NGUyL3RhYmxlOjdiMzY0ZTJjNGQ0MzRhZjVhZmUzNTlkYzVlMmNjYjg0L3RhYmxlcmFuZ2U6N2IzNjRlMmM0ZDQzNGFmNWFmZTM1OWRjNWUyY2NiODRfMC0xLTEtMS0xNzM_424735ed-3240-4de7-9193-4c4c8870da23">0001746473</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF84OS9mcmFnOmE1NTQxYmFkOTUyYzRlYjlhMTk1ZDJiZjc4ZmY2NGUyL3RhYmxlOjdiMzY0ZTJjNGQ0MzRhZjVhZmUzNTlkYzVlMmNjYjg0L3RhYmxlcmFuZ2U6N2IzNjRlMmM0ZDQzNGFmNWFmZTM1OWRjNWUyY2NiODRfMS0xLTEtMS0xODA_7bd15869-ce02-468d-9e9a-d0759f4e04fd">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDA3_ad22ad4a-b061-4b3e-b96c-a9611c2e2cb6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18xMDk5NTExNjI5MjI5_54a9e36d-a7ba-43d9-b3b5-a91099a2f630">2021-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDA5_8fa51eb2-98f2-416c-bed0-fde9eac6e0c1">PLIANT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTAtMS0xLTQy_ed3a7428-957e-41e6-9d07-9ec21a40af94">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTEtMS0xLTQ0_06d60eed-031f-46a4-803d-6a8f22a2ea77">001-39303</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8wLTItMS0xLTQ2_fbb55439-e469-4e09-bcb8-64b5ab06a4ce">47-4272481</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTc1NA_96455e93-3363-4b1f-b259-ffb50ab1cd84">260 Littlefield Avenue,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTg0NA_53924cbe-f453-4699-bf56-27004d4707dd">South San Francisco,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTAtMS0xLTcxL3RleHRyZWdpb246MzVkODkwZjc5MmVlNDgyZTg3YTY0OGM1ZmNhZTc0MDRfMjE5OTAyMzI1NTg1Mw_9ad3cae7-359a-4239-956d-6a64cdfde958">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6MWRjNGU2NWU2ZDljNDUzMjk4NTBkYjgyYjI4YTk4ZDkvdGFibGVyYW5nZToxZGM0ZTY1ZTZkOWM0NTMyOTg1MGRiODJiMjhhOThkOV8zLTItMS0xLTQ4_c6195df0-2527-4be4-aa5a-28a931a25044">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDEx_128faadc-71dc-4798-a58e-398e9e069556">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDIw_909cc578-d280-46a9-85d8-82f0ce7bdbe2">481-6770</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF8wLTAtMS0xLTEzOQ_0555803d-4ddc-421d-b465-e0964e134d9a">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF8yLTAtMS0xLTEzOQ_dffcf2ba-a908-48eb-b7f4-f6a1cb7e118e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF80LTAtMS0xLTEzOQ_6bbb8740-dc3e-47cc-b3ec-add4c504780e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6NDc5NzA2YTE1M2UwNDZiYzljZDljYzE4NWEwNzkyMTQvdGFibGVyYW5nZTo0Nzk3MDZhMTUzZTA0NmJjOWNkOWNjMTg1YTA3OTIxNF82LTAtMS0xLTEzOQ_7a9360ca-ae9b-45c7-bb5d-22585d4d68df">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTAtMS0xLTE0MQ_43c6640c-3fab-4ee7-8df4-7567b2243ffd">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTItMS0xLTE0Mw_0d246cb2-283f-49e0-a470-e692c76dc724">PLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGFibGU6YTZiYTRkZmQ2NjdiNGQ1N2IxNmU2MWVhYTY4NGExMzYvdGFibGVyYW5nZTphNmJhNGRmZDY2N2I0ZDU3YjE2ZTYxZWFhNjg0YTEzNl8xLTQtMS0xLTE0NQ_ab4484e2-96d2-473e-9f38-0c696b7905ae">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDIz_8dcd9de6-a6ce-46bf-948a-19ae5b4cc555">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyODJiMWM1MzFjNjRlMDZhMTYyMjhmZjMxMDdlY2EwL3NlYzo1MjgyYjFjNTMxYzY0ZTA2YTE2MjI4ZmYzMTA3ZWNhMF8xL2ZyYWc6NTJlNTA5YmU3OWJiNDA2MmJkODVmMTZlNmQzNDVkYjMvdGV4dHJlZ2lvbjo1MmU1MDliZTc5YmI0MDYyYmQ4NWYxNmU2ZDM0NWRiM18yMTk5MDIzMjU3MDI2_5c64f026-5f91-4e6b-a800-941efd0d1336">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139643333151096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLIANT THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4272481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">260 Littlefield Avenue,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001746473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( "N&JE+0)\@Q[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( "N&JE*97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *X:J
M4CE^C?=9!   VA   !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( "N&JE*?H!OPL0(  .(,   -
M      "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ *X:J4I>*NQS
M    $P(   L              ( !>0\  %]R96QS+RYR96QS4$L! A0#%
M  @ *X:J4JK$(A8S 0  (@(   \              ( !8A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( "N&JE(D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M "N&JE)ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plrx-20210510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plrx-20210510.htm">plrx-20210510.htm</File>
    <File>plrx-20210510.xsd</File>
    <File>plrx-20210510_cal.xml</File>
    <File>plrx-20210510_def.xml</File>
    <File>plrx-20210510_lab.xml</File>
    <File>plrx-20210510_pre.xml</File>
    <File>plrx-8kxexhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plrx-20210510.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "plrx-20210510_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plrx-20210510_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plrx-20210510.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plrx-20210510_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plrx-20210510_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plrx-20210510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plrx",
   "nsuri": "http://www.pliantrx.com/20210510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20210510.htm",
      "contextRef": "iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.pliantrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20210510.htm",
      "contextRef": "iaf8247d4cb704712a2bc7f24f4e68da8_D20210510-20210510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001746473-21-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001746473-21-000005-xbrl.zip
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M3V#M;>[6SIU\_]S5W)C.X;]A%H5[_P]02P,$%     @ *X:J4FU09\>' @
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M442)!JP$8>#;<EF)/#8HG\0YA3I[(*MV[:>QLPE'1M$R_U88UN;:@\%JO,$
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M<?E1Z3+HJ(C?R-#3VEAF$SA3K.%0,SEE[IAVB"*%]0%@?J J)1\1H'^8%N_
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M-KF+(5'R/C^ ""+]&48SCA5](D-[#KP!!#A;#N63TT23LI EJ;$<I$C?YC$
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M,C R,3 U,3 N:'1M4$L! A0#%     @ *X:J4FU09\>' @  =PD  !$
M         ( !B14  '!L<G@M,C R,3 U,3 N>'-D4$L! A0#%     @ *X:J
M4C*N2K^! 0  Q@(  !4              ( !/Q@  '!L<G@M,C R,3 U,3!?
M8V%L+GAM;%!+ 0(4 Q0    ( "N&JE(F).#@!P(  &L&   5
M  "  ?,9  !P;')X+3(P,C$P-3$P7V1E9BYX;6Q02P$"% ,4    "  KAJI2
M^9<_RIH*  "/80  %0              @ $M'   <&QR>"TR,#(Q,#4Q,%]L
M86(N>&UL4$L! A0#%     @ *X:J4I5\G*/>!@  @S,  !4
M ( !^B8  '!L<G@M,C R,3 U,3!?<')E+GAM;%!+ 0(4 Q0    ( "N&JE*6
M_W#+O!L  +LT 0 6              "  0LN  !P;')X+3AK>&5X:&EB:70Y
<.3$N:'1M4$L%!@     '  < S@$  /M)      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
